Trypa-NO! contributes to the elimination of gambiense human African trypanosomiasis by combining tsetse control with "screen, diagnose and treat" using innovative tools and strategies

PLoS Negl Trop Dis. 2020 Nov 12;14(11):e0008738. doi: 10.1371/journal.pntd.0008738. eCollection 2020 Nov.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Protozoan / blood
  • Chad
  • Cote d'Ivoire
  • Disease Vectors
  • Guinea
  • Humans
  • Insect Control / methods
  • Insecticides / administration & dosage
  • International Cooperation*
  • Mass Screening / methods*
  • Trypanosoma brucei gambiense / drug effects*
  • Trypanosoma brucei gambiense / isolation & purification
  • Trypanosoma brucei rhodesiense / drug effects*
  • Trypanosoma brucei rhodesiense / isolation & purification
  • Trypanosomiasis, African* / diagnosis
  • Trypanosomiasis, African* / drug therapy
  • Trypanosomiasis, African* / prevention & control
  • Tsetse Flies / parasitology
  • Uganda

Substances

  • Antibodies, Protozoan
  • Insecticides

Grants and funding

This project has been funded by the Bill & Melinda Gates Foundation, Grant No. OPP1104516 to ML and ST (LSTM) and Nos. OPP1154033 and INV-001785 to JN (FIND); the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme, supported by the European Union, grant number DRIA-2014-306-DiTECT-HAT to VL; the Republic and Canton of Geneva, Grant Nos. 248-2015 and 5704-2018 to JN; the Swiss Government, Grant Nos. 81019551 and 81050188 to FIND; and UK aid from the UK government, Grant No. 204074-101 and 300341-102 to FIND. Vestergaard SA is currently donating all the Tiny Targets used in this project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.